Cytokinetics

8 hours ago · globenewswire.com

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poster presentation, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, held in collaboration with the American Heart Association Scientific Sessions, taking place in Chicago, IL, November 6, 2026.

5 days ago · zacks.com

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12 days ago · globenewswire.com

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

14 days ago · globenewswire.com

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.

14 days ago · zacks.com

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

14 days ago · globenewswire.com

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.

21 days ago · globenewswire.com

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM

1 month ago · globenewswire.com

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

1 month ago · globenewswire.com

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice

1 month ago · marketbeat.com

Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.